Elevated circulating vaspin levels were decreased by rosiglitazone therapy in T2DM patients with poor glycemic control on metformin alone

Cytokine

Volumn 56, Issue 2, 2011, Pages 399-402

  Zhang, Lili ^a   Li, Ling ^a   Yang, Mengliu ^a   Liu, Hua ^b   Yang, Gangyi ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Insulin sensitivity; Rosiglitazone; Type 2 diabetes; Vaspin

Indexed keywords

GLUCOSE; INSULIN; METFORMIN; ROSIGLITAZONE; VASPIN;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DIET RESTRICTION; DISEASE ASSOCIATION; FEMALE; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HOMEOSTASIS; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; TREATMENT DURATION;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; MIDDLE AGED; SERPINS; THIAZOLIDINEDIONES;

EID: 80053329458     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.07.003     Document Type: Article

References (22)

1. Narayan K.M., Boyle J.P., Thompson T.J., Gregg E.W., Williamson D.F. Effect of BMI on lifetime risk for diabetes in the US. Diabetes Care 2007, 30:1562-1566.
2. Fruhbeck G. Overview of adipose tissue and its role in obesity and metabolic disorders. Methods Mol Biol 2008, 456:1-22.
3. Hida K., Wada J., Eguchi J., Zhang H., Baba M., Seida A., et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA 2005, 102:10610-10615.
4. Tan B.K., Heutling D., Chen J., Farhatullah S., Adya R., Keay S.D., et al. Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance. Diabetes 2008, 57:1501-1507.
5. Kloting N., Berndt J., Kralisch S., Kovacs P., Fasshauer M., Schon M.R., et al. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun 2006, 339:430-436.
6. Gulcelik N.E., Karakaya J., Gedik A., Usman A., Gurlek A. Serum vaspin levels in type 2 diabetic women in relation to microvascular complications. Eur J Endocrinol 2009, 160:65-70.
7. Youn B.S., Kloting N., Kratzsch J., Lee N., Park J.W., Song E.S., et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 2008, 57:372-377.
8. Seeger J., Ziegelmeier M., Bachmann A., Lossner U., Kratzsch J., Bluher M., et al. Serum levels of the adipokine vaspin in relation to metabolic and renal parameters. J Clin Endocrinol Metab 2008, 93:247-251.
9. Tonjes A., Fasshauer M., Kratzsch J., Stumvoll M., Bluher M. Adipokine pattern in subjects with impaired fasting glucose and impaired glucose tolerance in comparison to normal glucose tolerance and diabetes. PLoS One 2010, 5:e13911.
10. Hamann A., Garcia-Puig J., Paul G., Donaldson J., Stewart M. Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone. Exp Clin Endocrinol Diabetes 2008, 116:6-13.
11. Pfutzner A., Marx N., Walcher D., Lobig M., Seidel D., Forst T. Impact of rosiglitazone on visfatin and adiponectin plasma concentrations in patients with type 2 diabetes and coronary artery disease. Clin Lab 2008, 54:237-241.
12. Rizos C.V., Liberopoulos E.N., Mikhailidis D.P., Elisaf M.S. Pleiotropic effects of thiazolidinediones. Expert Opin Pharmacother 2008, 9:1087-1108.
13. Kadoglou N.P., Kapelouzou A., Tsanikidis H., Vitta I., Liapis C.D., Sailer N. Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and il-6 levels in drug-naive patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2011, 119:63-68.
14. Alberti K.G., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998, 15:539-553.
15. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
16. von Loeffelholz C., Mohlig M., Arafat A.M., Isken F., Spranger J., Mai K., et al. Circulating vaspin is unrelated to insulin sensitivity in a cohort of nondiabetic humans. Eur J Endocrinol 2010, 162:507-513.
17. Campbell I.W. The clinical significance of PPAR gamma agonism. Curr Mol Med 2005, 5:349-363.
18. Laplante M., Festuccia W.T., Soucy G., Gelinas Y., Lalonde J., Berger J.P., et al. Mechanisms of the depot specificity of peroxisome proliferator-activated receptor gamma action on adipose tissue metabolism. Diabetes 2006, 55:2771-2778.
19. Derosa G., Salvadeo S.A. Pioglitazone and rosiglitazone: effects of treatment with a thiazolidinedione on lipids and non conventional cardiovascular risk factors. Curr Clin Pharmacol 2008, 3:77-84.
20. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
21. Hsiao F.Y., Huang W.F., Wen Y.W., Chen P.F., Kuo K.N., Tsai Y.W. Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473, 000 patients using the National Health Insurance database in Taiwan. Drug Saf 2009, 32:675-690.
22. Diamond G.A., Bax L., Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 2007, 147:578-581.